New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on February 8, 2025.
Lilly Endowment Inc, a significant shareholder of Eli Lilly & Co, has recently sold 210,000 shares of the company’s stock. This transaction is valued at an impressive $183,566,194.
Recent Updates on LLY stock
Eli Lilly & Co. has seen positive developments with an analyst from BofA raising the firm’s price target due to strong Q4 results and promising FY25 EPS guidance, indicating alignment with consensus expectations. This adjustment is fueled by the company’s favorable earnings and outlook, without changes to forecasts for key products Mounjaro or Zepbound. Additionally, Eli Lilly announced promising results from its VIVID-2 study, showing long-term benefits for patients with Crohn’s disease treated with Omvoh, further supporting positive sentiment around the company.
More about Eli Lilly & Co
YTD Price Performance: 11.86%
Average Trading Volume: 3,949,420
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $826.3B
Questions or Comments about the article? Write to editor@tipranks.com